Kevin S. Harris
Corporate Officer/Principal bei American Society for Virology
Profil
Kevin Harris is Virology Director of Koronis Pharmaceuticals, Inc. and a Member of the American Society for Virology.
Prior to joining Koronis Pharmaceuticals, he was a Senior Molecular Biologist at Abbott Laboratories.
Dr. Harris received a PhD from SUNY Stony Brook in 1994.
Aktive Positionen von Kevin S. Harris
| Unternehmen | Position | Beginn |
|---|---|---|
| American Society for Virology | Corporate Officer/Principal | 17.04.2009 |
Ehemalige bekannte Positionen von Kevin S. Harris
| Unternehmen | Position | Ende |
|---|---|---|
| ABBOTT LABORATORIES | Corporate Officer/Principal | - |
Koronis Pharmaceuticals, Inc.
 Koronis Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Koronis Pharmaceuticals, Inc. develops antiviral therapeutics based on viral decay acceleration. Its therapeutics are designed to inhibit a specific viral protein or enzyme, drugs based on VDA are designed to provoke the rapid decay of the targeted virus by further increasing its naturally high rate of mutation. The company was founded by Richard Daifuku in 1998 and is headquartered in Seattle, WA. | Corporate Officer/Principal | - |
Ausbildung von Kevin S. Harris
| Stony Brook University | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| ABBOTT LABORATORIES | Health Technology |
| Private Unternehmen | 2 |
|---|---|
Koronis Pharmaceuticals, Inc.
Koronis Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Koronis Pharmaceuticals, Inc. develops antiviral therapeutics based on viral decay acceleration. Its therapeutics are designed to inhibit a specific viral protein or enzyme, drugs based on VDA are designed to provoke the rapid decay of the targeted virus by further increasing its naturally high rate of mutation. The company was founded by Richard Daifuku in 1998 and is headquartered in Seattle, WA. | Health Technology |
| American Society for Virology |
